Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: The analysis suggests the potentially harmful effect of Celebrex dosage is most pronounced in higher-risk patients, researchers said at the American College of Cardiology scientific meeting. "Patients at low cardiovascular risk should take some level of comfort," said Dr. Scott Solomon, lead researcher of the National Cancer Institute-sponsored analysis. "That wasn't so clear previously." Doctors should exercise caution in prescribing the drug, generally known as celecoxib, in high-risk patients, said Solomon, whose analysis was also published online in the journal Circulation. Celebrex belongs to a class of pain drugs known as cox-2 inhibitors and is the only such drug still on the market in the United States. Merck and Co Inc withdrew its widely used cox-2 drug, Vioxx, from the market in 2004 after a study showed it doubled the risk of heart attack and stroke in long- term users. Another cox-2 inhibitor from Pfizer called Bextra was also pulled from the U.S. market due to safety concerns. While the analysis sheds light on how the drug should be used, Solomon said he could not judge whether the data lift the cloud over this class of drugs. The six trials involving a total of 7,950 patients all studied Celebrex against a placebo for uses other than arthritis. Patients received either 400 milligrams once a day, 200 mg twice a day, or 400 mg twice a day. The primary goal of the pooled analysis was an assessment of the combined risk of cardiovascular death, heart attack, stroke, heart failure or events involving blood clots. Researchers found the heart risk was lowest at the 400 mg daily dose. They found nearly a two-fold risk of adverse heart events with the 200 mg twice daily dose and that jumped to about a three-fold risk at the 400 mg twice daily dose. "Even 400 mg once a day showed elevated risk" in the high-risk population, Solomon said, adding he could not extrapolate whether doses lower than 400 mg cut risk further. The increased risk was not affected by aspirin use, researchers said. "Most of the data used in this pooled analysis have previously been published and are consistent with what we already know about the cardiovascular risks of Celebrex and other prescription arthritis pain relievers," said Gail Cawkwell, Pfizer's executive medical director. "The analysis doesn't provide any new conclusions on the FDA-approved doses of Celebrex, including the most commonly prescribed dose of 200 mg daily," she said. Dr. Steven Nissen of the Cleveland Clinic, who has a study on lower doses underway, added: "There aren't long-term randomized placebo-controlled trials for that dose, The only way we're ever going to answer these questions is with good randomized prospective data," he said. "We'll tell it like it is when the data is in." Claim: Celebrex risky in high-risk patients, study finds.
[A]: Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday.

[Q]: Paragraph: The Virginia Department of Health said in a news release Saturday that the person visited the Richmond International Airport Tuesday night and a doctor's office in suburban Richmond on Thursday afternoon. The department posted detailed instructions online about what to do if you were at either of the locations during certain time frames. The directions depend on whether or not you have been vaccinated against measles. Based on the date of exposure, the health department said people infected could develop symptoms as late as January 11, 2020. Measles is a highly contagious illness spread though coughing, sneezing and contact with droplets from the nose, mouth or throat of an infection person. Symptoms include a fever, runny nose, watery red eyes and a cough, followed by a rash that begins on the face and spreads all over the body. Claim: Virginia health officials warn of possible measles exposure.
[A]: Virginia health officials are mounting an effort to identify people who may have recently been exposed to a person with measles.

[Q]: Paragraph: Bayer had previously disclosed 5,200 such lawsuits against Monsanto, which it acquired in a $63 billion deal completed in June. "The number of plaintiffs in both state and federal litigation is approximately 8,000 as of end-July. These numbers may rise or fall over time but our view is that the number is not indicative of the merits of the plaintiffs' cases," Bayer Chief Executive Werner Baumann told analysts in a conference call on Thursday. Bayer shares have lost more than 10 percent since Monsanto was ordered on Aug. 10 to pay $289 million in damages in the first U.S. lawsuit over glyphosate-based weedkillers such as Roundup and Ranger Pro. The legal headache adds to a number of distractions for Bayer, such as falling consumer care product sales and a rebuke on production practices from the U.S. drugs watchdog, as it seeks to strengthen its drug development pipeline and has begun integrating Monsanto into its organisation. "While this is disappointing, it is not surprising. Indeed, in our litigation scenario analysis, we assumed a doubling of cases to 10,400," said Alistair Campbell, analyst at brokerage Berenberg. Bayer shares were down 1.8 percent at 1600 GMT while the German blue chip index .GDAXI was up 0.2 percent. CEO Baumann reiterated Bayer's view that the jury's verdict on Aug. 10 was inconsistent with the science-based conclusions of regulators. Bayer said it will initially petition the judge to reverse the jury's verdict from Aug. 10, and "if necessary" challenge the ruling with California appellate courts, which will take at least a year. When asked whether Bayer would consider settling cases out of court, he said: "We will vigorously defend this case and all upcoming cases." Bayer executives on the call stressed that demand for glyphosate and seeds for crops that tolerate the broad-spectrum herbicide had not been affected by the verdict. "Nothing whatsoever has changed in the regulatory status of the product. There is simply very high demand, and has been for many decades for glyphosate. It is an invaluable tool for growers," said Liam Condon, the head of Bayer's newly enlarged Crop Science division. Bayer also said on Thursday that it sees no reason to re-assess the legal risks from Monsanto. Last week Bayer, which is retiring the Monsanto name, launched the integration of Monsanto into its organisation. That is seen as a daunting task even without the litigation, almost two years after it signed the $63 billion deal. Bayer's second-quarter results, due on Sept. 5, would include provisioning for legal defence costs but no money would at that point be set aside for any possible future damages, finance chief Wolfgang Nickl said. Claim: Bayer's Monsanto faces 8,000 lawsuits on glyphosate.
[A]:
The number of U.S. lawsuits brought against Bayer's (BAYGn.DE) newly acquired Monsanto has jumped to about 8,000, as the German drugmaker braces for years of legal wrangling over alleged cancer risks of glyphosate-based weedkillers.